Skip to main content
Premium Trial:

Request an Annual Quote

Epoch Biosciences Licenses Hybridization Technology from Applied Biosystems

NEW YORK, June 25 – Epoch Biosciences has licensed technology from Applied Biosystems for SNP detection and gene expression assays, the company said Monday. 

The technology, for using non-cleavable fluorescent self-quenching probes in hybridization assays, will be incorporated into the company’s assays for measuring gene expression and detecting SNPs. The company plans to release the first version of the assays this summer, in the launch of Epoch’s first product for the commercial market.

Epoch, based in Bothell, Wash., currently licenses its genetic analysis technology to Applied Biosystems and Third Wave Technologies, who use the technology for their commercial SNP detection and gene expression products.

Last year the company acquired Synthetic Genetics, a San Diego-based manufacturer of modified oligonucleotides, for $3.1 milion in cash.

"We are pleased to provide our probe technology to Epoch Biosciences as they near the release of their Eclipse probe line," Michael Lucero, vice president of applications marketing and R&D at Applied Biosystems, said in a statement.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.